NASDAQ:LXRX

Lexicon Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy LXRX

*Your capital is at risk

$2.31

-0.0300 (-1.28%)

At Close: Jul 31, 2026

Lexicon Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.57. In total, the insiders bought 5.64B and sold 676.67K LXRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	97.57
● Buy	5.64B shares
● Sell	676.67K shares
92% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 97.57. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Buy	Restricted Stock Units A-Award	Sullivan Diane E. Director	Director	35 714 Value: $58.2K
May 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Debbane Raymond Director	Director	43 478 Value: $70.0K
May 01, 2026 Buy	Restricted Stock Units A-Award	Debbane Raymond Director	Director	35 714 Value: $58.2K
Apr 30, 2026 Buy	Common Stock M-Exempt	Artal Participations S.a R.l.	Director	20 421 735 Value: $32.9M
Apr 30, 2026 Buy	Series B Convertible Preferred Stock A-Award	Artal Participations S.a R.l.	Director	408 435 Value: $657.6K
Apr 30, 2026 Buy	Series B Convertible Preferred Stock M-Exempt	Artal Participations S.a R.l.	Director	408 435 Value: $657.6K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Exton Michael Chief Executive Officer	CEO / President	503 263 Value: $1.16M
Feb 28, 2026 Sell	Common Stock F-InKind	Coiante Scott M SVP, Chief Financial Officer	C-Suite Officer	54 881 Value: $80.7K
Feb 28, 2026 Buy	Common Stock M-Exempt	Coiante Scott M SVP, Chief Financial Officer	C-Suite Officer	160 237 Value: $370.1K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Coiante Scott M SVP, Chief Financial Officer	C-Suite Officer	160 237 Value: $370.1K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Crum Brian T SVP, General Counsel & Secr.	Officer	33 457 Value: $77.3K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Crum Brian T SVP, General Counsel & Secr.	Officer	69 386 Value: $160.3K
Feb 28, 2026 Buy	Common Stock M-Exempt	Crum Brian T SVP, General Counsel & Secr.	Officer	69 386 Value: $160.3K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Crum Brian T SVP, General Counsel & Secr.	Officer	170 163 Value: $393.1K
Feb 28, 2026 Buy	Common Stock M-Exempt	Crum Brian T SVP, General Counsel & Secr.	Officer	33 457 Value: $77.3K
Feb 28, 2026 Sell	Common Stock F-InKind	Crum Brian T SVP, General Counsel & Secr.	Officer	105 019 Value: $154.4K
Feb 28, 2026 Buy	Common Stock M-Exempt	Crum Brian T SVP, General Counsel & Secr.	Officer	170 163 Value: $393.1K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Defrancesco Lisa SVP, Ir And Corp Comm	Officer	24 674 Value: $57.0K
Feb 28, 2026 Buy	Common Stock M-Exempt	Defrancesco Lisa SVP, Ir And Corp Comm	Officer	24 674 Value: $57.0K
Feb 28, 2026 Sell	Common Stock F-InKind	Defrancesco Lisa SVP, Ir And Corp Comm	Officer	74 572 Value: $109.6K
Feb 28, 2026 Buy	Common Stock M-Exempt	Granowitz Craig B SVP, Chief Medical Officer	Officer	202 260 Value: $467.2K
Feb 28, 2026 Sell	Common Stock F-InKind	Martens Rachel Yap SVP, Partnerships & Corp Strat	Officer	35 826 Value: $52.7K
Feb 28, 2026 Buy	Common Stock M-Exempt	Martens Rachel Yap SVP, Partnerships & Corp Strat	Officer	67 090 Value: $155.0K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Martens Rachel Yap SVP, Partnerships & Corp Strat	Officer	67 090 Value: $155.0K
Feb 28, 2026 Buy	Restricted Stock Units M-Exempt	Mcdermott Wendy SVP, Human Resources	Officer	27 697 Value: $64.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LEXICON PHARMACEUTICALS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The compan...

Read Full Profile Here